ScholarIQanswers from OpenAlex & ORCID
Taroh Satoh
ResearcherPublications, citations & collaboration network
Taroh Satoh is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Taroh Satoh have?
ScholarIQindexed works
Taroh Satoh has 515 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Taroh Satoh have?
ScholarIQcitation count
Taroh Satoh has 25,887 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Taroh Satoh?
ScholarIQh-index
Taroh Satoh has an h-index of 56 in OpenAlex.
What is the i10-index of Taroh Satoh?
ScholarIQi10-index
Taroh Satoh has an i10-index of 193 in OpenAlex.
What is the ORCID of Taroh Satoh?
ScholarIQorcid
The ORCID for Taroh Satoh is on the source record.
What is the OpenAlex record for Taroh Satoh?
ScholarIQopenalex
The OpenAlex for Taroh Satoh is on the source record.
What are the most-cited papers on Taroh Satoh?
ScholarIQmost cited works
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung, Guoping Sun, Toshihiko Doi, Jianming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jinwan Wang, Hiroto Miwa, Shukui Qin, Ik‐Joo Chung, Kun‐Huei Yeh, Jifeng Feng, Akihira Mukaiyama, Mikiro Kobayashi, Atsushi Ohtsu, Yung‐Jue Bang
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero, Elena Élez, Takayuki Yoshino, Alberto Sobrero, James C. Yao, Pilar García‐Alfonso, Judit Kocsis, Antonio Cubillo Gracián, Andrea Sartore‐Bianchi, Taroh Satoh, Violaine Randrian, Jiří Tomášek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Csőszi, Chiara Cremolini, François Ghiringhelli, Ardaman Shergill, Howard S. Höchster, John C. Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R. Schelman, Marek Kania, Josep Tabernero, Cathy Eng
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung‐Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Longzhen Zhang, Tienan Yi, Jong‐Mu Sun, Jianhua Chen, Guohua Yu, Chen‐Yuan Lin, Hiroki Hara, Qing Bi, Taroh Satoh, Roberto Pazo-Cid, Hendrick-Tobias Arkenau, Christophe Borg, Florian Lordick, Liyun Li, Ningning Ding, Aiyang Tao, Jingwen Shi, Eric Van Cutsem, for the RATIONALE-302 Investigators
Oncogene c-Myc promotes epitranscriptome m6A reader YTHDF1 expression in colorectal cancer
Yujiro Nishizawa, Masamitsu Konno, Ayumu Asai, Jun Koseki, Koichi Kawamoto, Norikatsu Miyoshi, Hidekazu Takahashi, Naohiro Nishida, Naotsugu Haraguchi, Daisuke Sakai, Toshihiro Kudo, Taishi Hata, Chu Matsuda, Tsunekazu Mizushima, Taroh Satoh, Yuichiro� Doki, Masaki Mori, Hideshi Ishii